Ursa Major to merge with Bleichroeder in $1.6B deal
Ursa Major merges with Bleichroeder Acquisition Corp III at $1.6B pre-money valuation. Post-transaction equity valuation set at approximately $2.3 billion. Deal supported by at least $350 million in PIPE commitments anchored by Inflection Point. Combined entity to trade on Nasdaq under ticker IPXX in Q1 2027.

*this image is generated using AI for illustrative purposes only.
Ursa Major Technologies has entered a definitive business combination agreement with Bleichroeder Acquisition Corp III to go public through a special purpose acquisition company (SPAC) merger.
The transaction reflects a pre-money equity valuation of approximately $1.6 billion and a post-transaction equity valuation of approximately $2.3 billion. The combined entity will trade on the Nasdaq under the ticker symbol IPXX following closing, which is anticipated in the first quarter of 2027. Upon closing, Ursa Major will be renamed Inflection Point Mach X Bleichroeder.
Transaction Structure
The deal is supported by at least $350 million in private investment in public equity (PIPE) commitments. Approximately $110 million of this amount will be funded at the signing of the business combination agreement. The PIPE commitment is anchored by Inflection Point Asset Management and includes both new institutional investors and existing Ursa Major investors, including XN.
Ursa Major may also retain up to $345 million in additional proceeds depending on shareholder redemptions from the SPAC trust. Proceeds are expected to accelerate the expansion of production capabilities across solid rocket motors, the HAVOC Missile System, liquid hypersonic engines, and space mobility systems.
| Metric | Value |
|---|---|
| Pre-money valuation | $1.6 billion |
| Post-transaction valuation | $2.3 billion |
| PIPE commitments | At least $350 million |
| Initial PIPE funding | $110 million |
| Potential retained proceeds | Up to $345 million |
The Board of Directors of both Ursa Major and Bleichroeder unanimously approved the transaction. An investor presentation by Ursa Major and Inflection Point will be recorded on August 25, 2026 at 8:30 a.m. ET.
What the Numbers Show
The capital raise represents a significant scaling event for a company that has previously raised approximately $380 million in private markets. The new post-transaction equity valuation of $2.3 billion implies a substantial premium over the cumulative private capital raised, reflecting investor confidence in the company’s flight-proven technology and manufacturing readiness. The inclusion of $110 million in immediate funding at signing provides near-term liquidity to support operations before the full closing proceeds are realized.
Operational Context
Founded in 2015, Ursa Major employs more than 360 people across six facilities, utilizing nearly 500 acres of integrated design, manufacturing, and testing infrastructure. The company has conducted more than 5,500 ground tests and 140,000 seconds of testing, with its engines powering more than a dozen successful hypersonic missions.
Key programs include:
- Advancing the U.S. Navy’s MK 104 design under a new $10 million award.
- Powering the Department of War’s hypersonic test bed with its Hadley engine, recording more than 10 successful missions.
- Serving as prime contractor for the Affordable Rapid Missile Demonstrator (ARMD) with the Air Force Research Laboratory, completing two successful flights.
Near-term capital will support the expansion of Ursa Major’s Galeton, Colorado operations from a test site into a large-scale production campus. Additional funds will support liquid engine manufacturing, additive manufacturing, all-up-round development, and working-capital needs associated with scaling production.
Cantor Fitzgerald & Co. serves as lead placement agent and lead financial advisor to Bleichroeder. Moelis & Company LLC serves as joint placement agent to Inflection Point and exclusive capital markets advisor to Ursa Major.
How might the anticipated Q1 2027 closing timeline impact Ursa Major's ability to secure and execute near-term defense contracts, such as the MK 104 program, given the gap between signing and liquidity realization?
What are the potential risks to the $2.3 billion post-transaction valuation if shareholder redemptions from the SPAC trust significantly reduce the retained proceeds below the maximum $345 million?
How will the transition to a public company structure influence Ursa Major's strategic partnerships with government entities like the Department of War and the Air Force Research Laboratory regarding intellectual property and data security?


























